Kirkwood, John M.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 7,720

Genomic classification of cutaneous melanoma

Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 3,151

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 1,781

Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy

Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell

Cancer Immunotherapy and BiomarkersVirus-based gene therapy research

Cited by 1,520

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,307

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 977

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine

Ocular Oncology and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 924

Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma

Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 919

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., et al. (2018) · The Lancet Oncology

Cutaneous Melanoma Detection and ManagementMelanoma and MAPK Pathways

Cited by 664

Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity

Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 627

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 394

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1

Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 372

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 219

Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609

Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., et al. (2020) · Journal of Clinical Oncology

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 184

Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells

Jost, L. M., Kirkwood, J. M., & Whiteside, T. L. (1992) · Journal of Immunological Methods

Immunotherapy and Immune ResponsesBioactive Compounds and Antitumor Agents

Cited by 182

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Ribas, A., Medina, T., Kirkwood, J. M., Zakharia, Y., Gonzalez, R., Davar, D., Chmielowski, B., Campbell, K. M., Bao, R., Kelley, H., et al. (2021) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 180

A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis

Sætrom, P., Biesinger, J., Li, S. M., Smith, D., Thomas, L. F., Majzoub, K., Rivas, G. E., Alluin, J., Rossi, J. J., Krontiris, T. G., et al. (2009) · Cancer Research

MicroRNA in disease regulationGenetic Associations and Epidemiology

Cited by 138

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression

Katlinskaya, Y. V., Katlinski, K. V., Yu, Q., Ortiz, A., Beiting, D. P., Brice, A., Davar, D., Sanders, C., Kirkwood, J. M., Rui, H., et al. (2016) · Cell Reports

Telomeres, Telomerase, and Senescenceinterferon and immune responses

Cited by 108

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 86

Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells

Shan, F., Cillo, A. R., Cardello, C., Yuan, D. Y., Kunning, S. R., Cui, J., Lampenfeld, C., Williams, A. M., McDonough, A. P., Pennathur, A., et al. (2023) · Science Immunology

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 38

Survival Is Not the Only Valuable End Point in Melanoma Screening

Curiel-Lewandrowski, C., Kim, C. C., Swetter, S. M., Chen, S. C., Halpern, A. C., Kirkwood, J. M., Leachman, S. A., Marghoob, A. A., Ming, M. E., & Grichnik, J. M. (2012) · Journal of Investigative Dermatology

Cutaneous Melanoma Detection and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 26

Anti-PD-1 antibody treatment for melanoma

Ribas, A., Kirkwood, J. M., & Flaherty, K. T. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 20

Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885

Chang, A. Y., Tu, Z. N., Bryan, G. T., Kirkwood, J. M., Oken, M. M., & Trump, D. L. (1994) · Investigational New Drugs

Renal cell carcinoma treatmentCancer therapeutics and mechanisms

Cited by 16